Sage Therapeutics (SAGE) PT Lowered to $84 at RBC Capital Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Sage Therapeutics (SAGE) PT Lowered to $90 at Wedbush, Following Earnings
May 4, 2021 11:32 AM EDTWedbush analyst Laura Chico lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $90.00 (from $98.00) while maintaining a Outperform rating.
... MoreSage Therapeutics (SAGE) PT Raised to $189 at Goldman Sachs, Following Earnings
May 4, 2021 11:11 AM EDTGoldman Sachs analyst Salveen Richter raised the price target on Sage Therapeutics (NASDAQ: SAGE) to $189.00 (from $187.00) while maintaining a Buy rating.
... MoreSAGE Therapeutics (SAGE) Tops Q1 EPS by 27c, Revenues Miss
May 4, 2021 7:16 AM EDTSAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($1.64), $0.27 better than the analyst estimate of ($1.91). Revenue for the quarter came in at $1.58 million versus the consensus estimate of $2 million.
Sage started 2021 with significant advances across our depression, neurology and neuropsychiatry franchises,... More
